Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Company

E Scott Priestley

Gregory S Bisacchi

Xiaojun Zhang

Zulan Pi

Timothy F Herpin

Uwe D Treuner

T G Murali Dhar

William A Slusarchyk

Carl P Decicco

Peter W Glunz

George C Morton

Nicholas Ronald Wurtz

Daniel L Cheney

Scott A Bolton

Alexandra Holubec

The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel 3,4-disubstituted benzamidines and benzylamines, or a stereoisomer or pharmaceutically acceptable salt form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor Xa, factor XIa, factor IXa, and/or factor VIIa. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors

The present invention relates to lactams of Formula (I):or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

Lactam inhibitors of Hepatitis C virus NS3 protease

Compounds having the formula (I), or a stereoisomer or pharmaceutically-acceptable salt, or hydrate thereof, are useful as factor VIIa inhibitors, wherein X is &#x2014;NRS(O)R; W is hydrogen or &#x2014;(CRR)W; Wis hydrogen or a bond with R; Z is a-membered heteroaryl group, a five to six membered heterocyclo or cycloalkyl group, atomembered bicyclic aryl or heteroaryl, or a six membered aryl or heteroaryl, and R, R, R, R, R, and Rare as defined in the specification.

Phenylglycine derivatives useful as serine protease inhibitors

Methods of treating Factor VIIa-associated conditions in a mammal are described, comprising administering to the mammal in need of treatment thereof an effective amount of at least one compound having the formula (I), or a pharmaceutically-acceptable salt, hydrate or prodrug thereof.

Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus

This invention relates to a novel class of peptides having the Formula (I):which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus (HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.

Peptide inhibitors of hepatitis C virus NS3 protease

This invention relates to a novel class of peptides having the Formula (I):which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus(HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.

Peptide inhibitors of Hepatitis C virus NS3 protein

Compounds having the formula (I),or pharmaceutically-acceptable salts, hydrates or prodrugs thereof, are effective as inhibitors of Factor VIIa.

Growing community of inventors

Yardley, PA, United States of America

E Scott Priestley